Company intelligence / Profile preview
Rebel Medicine
- Ownership
- Private
- Development stage
- Other
Overview
Rebel Medicine develops non-opioid solutions for acute pain. Its lead product, Alevatrix™, is a long-lasting injectable local anesthetic designed to provide up to 72 hours of postoperative pain relief without opioids. The company has completed preclinical large animal studies and a pre‑IND meeting with the FDA. It has raised $3M in seed funding and $1.8M in grants from NSF, NIH, and Utah state agencies. Additional pipeline programs include once-monthly peptide delivery for metabolic diseases using their proprietary platform.
- Therapeutic areas
- Metabolic DisordersNeurology
- Modalities
- Injectable long-acting local anestheticsDrug delivery platforms for peptides and small molecules
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on Rebel Medicine.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rebel Medicine.